The Future is NOW for Continuous Manufacturing - Part 3 — Multi-Column Continuous (MCC) Chromatography

Dr. Kathleen Mihlbachler
Global Director of Separation Development
LEWA Process Technologies

15-01-2015





Objective

Introduce Process Chromatography and in particular MCC and SMB Chromatography for synthetic and bio-molecules

Highlight challenges and how to overcome them

Drivers are:

Introducing continuous manufacturing and integrated DSP


Increased titers of fermentation processes, and continuous upstream technologies; thus, DSP the "bottleneck"


Improve production rate and robustness and reduce capital and operational costs of pharmaceutical processes





01/15/2015


Multi-Column Continuous Chromatography

















Challenges of MCC Chromatography

Advantages of SMB Chromatography:

Established technology for 24/7 operation

Process design tools based on thermodynamic (adsorption isotherms and kinetic (mass transfer) principles

Reduced operational costs by reduced solvent consumption, increased product purities and productivities
Safe, economical and environmental friendly processing


Reduced capital costs for equipment (skids and columns), packing materials, and facilities


Eliminates holding points due to continuous operation


SPE


01/15/2015


Multi-Column Continuous Chromatography











Challenges of MCC Chromatography

Complex feed solutions that might vary in composition

Implementation of PAT tools: online/inline UV detectors, pH and conductivity meters

Limited experience in transfer batch to continuous operation for biomolecules (existing processes vs process design for new molecules)

Mechanical and chemical stability of resin (caustic wash) and packing characteristics (shrinking and expanding)

Increased loadibility (concentration step on column), however, due to the continuous operation longer/higher loads – packing life time

24/7 operation - cleanability (CIP/SIP and re-equilibration) and life time



01/15/2015

Multi-Column Continuous Chromatography

Regulatory Challenge

API of biopharmaceutical processes created in fermenter, not in the last step of the processing scheme of synthetic molecules.

Transition from batch to continuous 24/7 processing

Exposure time of molecule to process conditions causing any denaturation, association, or aggregation; therefore, immunogenic reactions

Risk assessment of the product, process and equipment based on ICH Q9



01/15/2015

Multi-Column Continuous Chromatography

17

Regulatory Challenge

QC/QA (impurity profile), product and process comparability, deviations

Validation of the MCC process for cGMP environment.

- Definition of batch size
- Batch integrity
- CIP protocol for continuous process
- Long-term testing to guarantee the cleanability



01/15/2015

Multi-Column Continuous Chromatography

How to overcome all of the challenges?

By implementing MCC Chromatography

into the pharmaceutical manufacturing processes



01/15/2015

Multi-Column Continuous Chromatography

19

ありがとう.



Thank you!



Danke!

contact: KMihlbachler@LEWApt.com

SPE

www.LEWA.com or www.NIKKISO.com

01/15/2015

Multi-Column Continuous Chromatography